Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program.
Controversies regarding the pathophysiology of neonatal alloimmune thrombocytopenia (NAIT) has hampered the development of consensus about how to identify, follow up and treat the women and children with this serious complication. One reason for this is that knowledge about the condition derived from previous retrospective studies do not necessarily conform with data derived from prospective investigations. The main obstacle to introduction of general screening programs to identify the pregnancies to treat, have been lack of reliable risk factors, and an effective treatment. Now, several recent prospective screening programs including up to 100,000 pregnant women has changed the understanding of the NAIT-pathology, and has shown that we are close to answering these critical questions.
Skogen
B
B
Immunology and Transfusion Medicine, University Hospital of North Norway, Tromsø, Norway. bjorn.skogen@unn.no
Husebekk
A
A
Killie
M K
MK
Kjeldsen-Kragh
J
J
D001792:Blood Platelets / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D039661:Integrin beta3 / Q000276:immunology* / Q000378:metabolism; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D011296:Prenatal Diagnosis; D054098:Thrombocytopenia, Neonatal Alloimmune / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*
D039661:Integrin beta3